Mesoblast (MESO) said Sunday it has entered into the Medicaid National Drug Rebate Agreement with the US Centers for Medicare and Medicaid Services for Ryoncil, a US Food and Drug Administration therapy for any indication.
The agreement means that the US government will provide inpatient and outpatient access to Ryoncil as a treatment for children with steroid-refractory acute graft versus host disease who are covered by Medicaid.
The company said the first three children with the life-threatening condition that often follows organ transplants will receive a course of Ryoncil beginning this week.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.